Exelixis, Inc. (EXEL)
Automate Your Wheel Strategy on EXEL
With Tiblio's Option Bot, you can configure your own wheel strategy including EXEL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EXEL
- Rev/Share 8.181
- Book/Share 7.4602
- PB 4.789
- Debt/Equity 0.0884
- CurrentRatio 3.513
- ROIC 0.232
- MktCap 9617744627.0
- FreeCF/Share 2.7473
- PFCF 12.8432
- PE 16.1689
- Debt/Assets 0.0672
- DivYield 0
- ROE 0.2774
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | EXEL | Leerink Partners | Market Perform | Outperform | -- | $48 | Oct. 21, 2025 |
| Resumed | EXEL | Barclays | -- | Equal Weight | -- | $40 | Sept. 19, 2025 |
| Resumed | EXEL | Barclays | -- | Equal Weight | -- | $40 | Sept. 17, 2025 |
| Initiation | EXEL | Goldman | -- | Buy | -- | $47 | Sept. 17, 2025 |
| Downgrade | EXEL | RBC Capital Mkts | Outperform | Sector Perform | $45 | $50 | July 8, 2025 |
| Upgrade | EXEL | Stephens | Equal Weight | Overweight | -- | $60 | June 24, 2025 |
| Downgrade | EXEL | Wells Fargo | Overweight | Equal Weight | -- | $36 | Feb. 24, 2025 |
| Upgrade | EXEL | Morgan Stanley | Equal Weight | Overweight | $30 | $40 | Jan. 27, 2025 |
| Downgrade | EXEL | Oppenheimer | Outperform | Perform | -- | -- | Jan. 24, 2025 |
| Downgrade | EXEL | BMO Capital Markets | Outperform | Market Perform | $36 | $40 | Dec. 20, 2024 |
News
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Published: July 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Top-ranked stocks Urban Outfitters (URBN), Fox (FOX), Electronic Arts (EA), Uber Technologies (UBER) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Read More
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
Read More
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
2 Stocks to Buy With Less Than $50
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive
One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.
Read More
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
Read More
3 Stocks With Upgraded Broker Ratings to Consider for Solid Returns
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL, LYFT and KGC have all seen notable broker upgrades recently. Here???s why they may offer solid returns ahead.
Read More
3 Reasons Growth Investors Will Love Exelixis (EXEL)
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Read More
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL jumps 7.4% as STELLAR-303 trial hits key survival goal in colorectal cancer, boosting hopes for an approval of zanzalintinib.
Read More
Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Positive
Exelixis is a strong buy due to robust CABOMETYX sales growth, with Q1 2025 revenues up 36% year-over-year and raised full-year 2025 guidance. Positive phase 3 STELLAR-303 results for zanzalintinib plus TECENTRIQ in non-MSI-high metastatic colorectal cancer opens significant new market opportunities. Expansion of the zanzalintinib pipeline into additional indications (nccRCC, HNSCC) and ongoing regulatory milestones could further drive shareholder value.
Read More
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
Published: June 22, 2025 by: Business Wire
Sentiment: Neutral
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from.
Read More
Here's Why Exelixis (EXEL) is a Strong Value Stock
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
EXEL or ARGX: Which Is the Better Value Stock Right Now?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Negative
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Read More
3 Underfollowed Stocks on the Move Now (OLO, PLMR, EXEL)
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
I like to keep things simple—I look for stocks that have strong price momentum, top Zacks Ranks, reasonable valuations and high growth forecasts. Momentum indicates that the market recognizes a winner, the Zacks rank reflects improving analyst expectations, a reasonable valuation limits downside risk and growth is what ultimately drives stock returns.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Exelixis (EXEL) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
EXEL gains 28.2% YTD, driven by Cabometyx growth, pipeline progress and an increase in stock buyback authorizations.
Read More
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
About Exelixis, Inc. (EXEL)
- IPO Date 2000-04-17
- Website https://www.exelixis.com
- Industry Biotechnology
- CEO Michael M. Morrissey
- Employees 1147